12 results
Thumbnail

D2.325 - Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study

Thumbnail

D2.326 - Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study

Thumbnail

D2.327 - Outcome of hematopoietic stem cells transplantation for inborn error of immunity in Vietnam

Thumbnail

D2.328 - Comparison of the frequency of viral infections in immunocompromised patients receiving immunoglobulin by different routes

Thumbnail

D2.329 - Impact of Berotralstat on Quality of Life among Patients with Hereditary Angioedema: Pooled Analysis of the APeX-2 and APeX-J Trials

Thumbnail

D2.330 - Hereditary angioedema prophylaxis therapy: berotralstat and lanadelumab safety profile

Thumbnail

D2.331 - Lanadelumab safety and efficacy in patients aged ≥12 with hereditary angioedema (HAE) in China for long-term prophylaxis (LTP): An open-label, multicenter study

Thumbnail

D2.334 - Real-World Effectiveness of Lanadelumab in Hereditary Angioedema: A 12-Month Retrospective Study at a Single Center in Colombia

Thumbnail

D2.336 - Evolution of Hereditary Angioedema Prophylaxis in Hungary Over Four Decades (1979-2023)

Thumbnail

D2.338 - The Effect of Covid-19 Vaccines on Adult Primary Immunodeficiency Patients

Thumbnail

D2.339 - Hereditary Angioedema Burden: Impact on Quality of Life, Disease Management, and Sleep Health

Thumbnail

D2.340 - A high prevalence of autoimmune diseases and autoantibodies in patients with hereditary angioedema in Sweden